A. Shenoy

Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients

Balaswamy Reddy, V. Lokesh, M. S. Vidyasagar et al. · Oral Oncology · 2014 · 109 citations

Medicine, Oncology, Pharmacotherapy +6

An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study.

K. Govind Babu, Lokesh Viswanath, Balaswamy Reddy et al. · Journal of Clinical Oncology · 2010 · 37 citations

Medicine, Oncology, Radiation Oncology +16

A phase IIb 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer

B. Krishnamurthyreddy, M. S. Vidyasagar, Reshma Koteshwar et al. · Journal of Clinical Oncology · 2009 · 12 citations

Medicine, Oncology, Radiation Oncology +17